THADEMARKS THADEMARKS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

V

IFW

In re Applicant:

Tamar TENNENBAUM et al

Serial No.:

10/644,775

Filed:

August 21, 2003

For: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS

Examiner:

Group Art Unit: 1615

Attorney

Docket: 26306

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Enclosed is a PTO Form 1449 which lists citations which may be material to the patentability and examination of the above identified application. Also enclosed are copies of the references cited. These are submitted in compliance with the duty of disclosure defined in 37 CFR 1.56. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement under 37 CFR 1.56 is not to be construed as a representation that a search has been made, that additional matter which is material to the examination of this application does not exist, or that any or more of these citations constitutes prior art.

Respectfully submitted,

So'l Sheinbein

Registration No. 25,457

Dated: January 13, 2005

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the D	nanyark	Reduction Act (2) 1995, no persons	a required to resr	ond to a col	U.S.Pat	ent and Trademark Off	ce; U.S. DE	EPARTMENT OF COMME	RC	
Onder the Pa	aperwork	Substitute for form 1449A/	are required to resp	John to a cor	lection of the		lete if Kno			
Substitute for form T449A/PTO							44,775			
INFORMATION DISCLOSURE						ate	August 21, 2003			
					First Nar	ned Inventor		IENBAUM		
STATEMENT BY APPLICANT					Art Unit					
(use as many sheets as necessary)						r Name				
Sheet	heet 1 of 3			Attorney	ey Docket Number 26306					
			U.S. PA	TENT	DOCUM	ENTS				
Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document			Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
	1	Number-Kind Code ^{2 (if known)}	00.0.1002			YY:				
	1	US-5,145,679	08-8-1992			Hinson	-			
	2	US-4,833,257	05-23-1989	,	Pettit et al. Lindenbaum					
	3	US-5,591,709	07-7-1997							
	4	US-5,461,030	10-24-1995			Lindenbaum				
···	5	US-2002/119914	08-29-2002	2	Zhu et al.		 			
<u> </u>								-		
,			-			······································			_	
		, , , , , , , , , , , , , , , , , , , ,								
·										
·										
			FOREIGN	PATE	NT DOC	UMENTS				
Examiner Initials*	Cite No. 1	Foreign Patent Documents		Publication Date MM-DD-YYYY		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages	T	
	1		Number ⁴ -Kind Code ⁵ (if known)		006			or Relevant Figures Appear	\vdash	
	6	PCT WO 96/23522		08-8-1996		Zimmet			\vdash	
	7	EP 0679402	02-2-1		Yoshida et al.			 		
	8	EP 0561330		09-22-		Liedtke				
	9	PCT WO 99/35283		07-15-1999 Mercurio et al.				\vdash		
	10	PCT WO 92/18147			0-29-1992 Owen et al.				ـ	
	11	PCT WO 99/18920	04-22-1999 11-21-1985		Zhu			igspace		
	12	PCT WO 85/05036			Weber et al.			↓_		
	13	PCT WO 96/09810	04-4-1		Gilchrest et al.			 		
	14	PCT WO 96/20724	07-11-1996		Hartman et al.			 		
	15	WO 01/76650		10-18-2001		Newell et al.			\perp	
				1		1		I	1	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner

Signature

Date

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

		bstitute for form 1449A/PTO	nation unless it contains a valid OMB control number. Complete if Known					
	Su	Datitute for forth 1443/VF FO	Application Number 1		10/644,775			
	INF	ORMATION DISCLOSURE	Filing Date	August 21, 2003				
	STA	TEMENT BY APPLICANT	First Named Inventor		TENNENBAUM			
(use as many sheets as necessary)			Group Art Unit 1615					
			Examiner Name					
Sheet	2	Of 3	Attorney Docket Number	26306				
		OTHER PRIOR ART – NON PATENT LITERA	ATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.						
	16	Ferber et al. "Pancreatic and Duodenal Homeobox Gene 1 Induces Expression of Insulin Genes in Liver and Ameliorates Streptozotocin-Induced Hyperglycemia", Nature Medicine, 6(5): 568-572, 2000.						
	17	Hengge et al. "Epidermis as Target for In Vivo Gene-Therapy", Journal of Investigative Dermatology, 105(3): 448, 1995. Abstract.						
	18	Setoguchi et al. "Ex Vivo and In Vivo Gene Transfer to the Skin Using Replication- Deficient Recombinant Adenovirus Vectors", The Journal of Investigative Dermatology, 102(4): 415-421, 1994.						
	19	Ohba et al. "Induction of Differentiation in Normal Human Keratinocytes by Adenovirus-Mediated Introduction of the Eta and Delta Isoforms of Protein Kinase C", Molecular and Cellular Biology, 18(9): 5199-5207, 1998.						
	20	Macfarlane et al. "Glucose Stimulates Translocation of the Homeodomain of Transcription Factor PDX1 From the Cytoplasm to the Nucleus of Pancreatic Bet-Cells", J. Biol. Chem., 274(2): 1001-1016, 1999.						
_	21	Lindenbaum et al. "Serum-Free Cell Culture Medium Induces Acceleration of wound Healing in Guenia-Pigs", Burns, 21(2): 110-115, 1995.						
	22	Braiman et al. "Protein Kinase C-Delta Mediates Insulin-Induced Glucose Transport in Primary Cultures of Rat Skeletal Muscle", Molecular Endocrinology, 13(12): 2002-2012, 1999.						
	23	Jeschke et al. "Effect of Multiple Gene Transfers of Insulinlike Growth Factor I Complementary DNA Gene Constucts in Rats After Thermal Injury", Archives of Surgery, 134(10): 1137-1141, 1999.						
	24	Braiman et al. "Tyrosine Phosphorylation of Specific Protein Kinase C Isoenzymes Participates in Insulin Stimulation of Glucose Transport in Primary Cultures of Rat Skeletal Muscle", Diabetes, 48(10): 1922-1929,1999.						
	25	Bitar et al. "Insulin and Glucocorticoid-Dependent Sup Diabetic Wounds", Surgery, 127(6): 687-695, 2000.	pression of the IGF-I Sy	stem I				
	26	Pittelkow et al. "Serum-Free Culture of Normal Human Melanocytes: Growth Kinetics and Growth Factor Requirements", Journal of Cellular Physiology, 140(3): 565-576, 1989.						
	27	Andre et al. "Protein Kinases C-Gamma and -Delta Are Involved in Insulin - Like Growth Factor I- Induced Migration of Colonic Epithelial Cells", Gastroenterology, 116(1): 64-77, 1999.						
	28	Shen et al. "PKC Delta Activation: A Divergence Point in the Signaling of Insulin and IGF-1-Induced Proliferation of Skin Keratinocytes", Diabetes, 50(2): 255-264, 2001.						
	29	Spravchikov et al. "Glucose Effects on Skin Keratinocytes: Implications for Diabetes Skin Complications", Diabetes, 50(7): 1627-1635, 2001.						
	30	Jeschke et al. "IGF-I Gene Transfer in Thermally Injured Rats", Gene Therapy, 6(6): 1015-1020, 1999.						
Examiner			Date					
Signature			Considered					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

1. Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Panerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperw	ork Reduction	on Act of 1995, no persons are required to respond to a collect	ion of information unle	ess it contains a valid OMB control i	number.			
		ubstitute for form 1449A/PTO	Complete if Known					
	5	ubstitute for form 1449AVF TO	Application Number	10/644,775				
	INF	ORMATION DISCLOSURE	Filing Date	August 21, 2003				
			First Named Inventor	TENNENBAUM				
STATEMENT BY APPLICANT (use as many sheets as necessary)				Group Art Unit	1615			
				Examiner Name				
Sheet	3	Of	3	Attorney Docket Number	26306			
	31	Taran et al. "Improved Vitality of Expertment of Treated With Enriched Cell Culture Me 104(1): 148-151, 1999.		•	•			
	32	Spravchikov et al. "The Interactive Effects of Hyperglycemia, Insulin and IGF-1 in Murine Skin Cells: An Ir-Null Mouse Model", Diabetologia, 43(Suppl.1): A 176, 2000.						
	33	Wertheimer et al. "The Regulation of Skin Proliferation and Differentiation in the IR Null Mouse: Implications for Skin Complications of Diabetes", Endocrinology, 142(3): 1234-1241, Mar 2001.						
Examiner				Date				
Signature				Considered				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

^{1.} Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.